CTNI-79. PRICOTTF TRIAL: A PHASE I/II TRIAL OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA

OBJECTIVE: Survival rates were significantly improved when adding TTFields to adjuvant chemotherapy with temozolomide in patients with newly diagnosed glioblastoma (nGBM) in the phase 3 EF-14 trial. TTFields therapy is applied at 200 kHz by arrays that are placed at the patients’ scalp. In preclinic...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Kebir, Sied, Lazaridis, Lazaros, Schmidt, Teresa, Oster, Christoph, Pierscianek, Daniela, Guberina, Nika, Kleinschnitz, Christoph, Proescholdt, Martin, Hau, Peter, Grosu, Anca-Ligia, Sure, Ulrich, Scheffler, Björn, Stuschke, Martin, Glas, Martin
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Clinical Trials: Non-Immunologic
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651594/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.245
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items